GLP-1s & Next-Gen Agonists
Semaglutide vs tirzepatide vs retatrutide (and related agents).
| Semaglutide Ozempic, Wegovy | Tirzepatide Mounjaro, Zepbound | Retatrutide LY3437943 | Cagrilintide | |
|---|---|---|---|---|
| Basic Information | ||||
| Status | FDA approved | FDA approved | Phase 3 clinical trials | Phase 3 clinical trials |
| Class | GLP-1 receptor agonist | GLP-1/GIP dual receptor agonist | GLP-1/GIP/Glucagon triple receptor agonist | Long-acting amylin receptor agonist |
| Mechanism | Activates GLP-1 receptors, enhancing insulin secretion, suppressing glucagon, slowing gastric emptyi... | Activates both GLP-1 and GIP receptors, enhancing insulin secretion, reducing glucagon, slowing gast... | Activates GLP-1, GIP, and glucagon receptors. The glucagon component may enhance energy expenditure ... | Activates amylin receptors, promoting satiety, slowing gastric emptying, and potentially preserving ... |
| Dosing | ||||
| Starting Dose | 0.25mg weekly | 2.5mg weekly | 1-2mg weekly (research protocols) | 0.3mg weekly (research protocols) |
| Half-life | ~7 days | ~5 days | ~6 days (estimated) | ~7 days |
| Administration | Subcutaneous injection (Ozempic/Wegovy) or oral (Rybelsus), once weekly | Subcutaneous injection, once weekly | Subcutaneous injection, once weekly | Subcutaneous injection, once weekly |
| Reported Outcomes (Grade) | ||||
| Weight Loss | B 233 | B 323 | A 694 | C 141 |
| Blood Sugar Control | C 147 | C 160 | C 153 | D 45 |
| Sleep Quality | C 128 | B 273 | A 523 | C 143 |
| Appetite Suppression | C 105 | B 185 | A 550 | B 247 |
| Mental/Mood | D 59 | C 79 | C 153 | D 44 |
| Body Composition | D 50 | D 55 | B 195 | D 21 |
| GI Health | D 62 | C 111 | B 227 | D 62 |
| Energy Levels | D 41 | C 117 | B 348 | C 145 |
| Common Side Effects | ||||
| Nausea | 14.2% | 7.4% | 8.2% | 13.1% |
| Constipation | 12.2% | 8.5% | 9.5% | 16.2% |
| Fatigue | 11.6% | 10.2% | 12.1% | 20.7% |
| Pricing | ||||
| US Research Grade | $75 | $100 | $100 | $80 |
| China Research Grade | $3.67 | $2.85 | $5.88 | $8.5 |
| Research & Community | ||||
| Research Articles | 1,345 | 477 | 32 | 11 |
| Community Posts | 1,248 | 3,333 | 5,896 | 1,824 |